Hangzhou Sartort Biopharma Co., Ltd

APIs&Intermediates,Fine chemicals,Ionic liquids and 3D printing materials

Hangzhou Sartort Biopharma Co., Ltd

Country: China (Mainland)Business Type: Lab/Research institutions

Manufacturer

Assessed supplierAssessed
supplier

qq

Contact US
Mr.Bob Yu
Tel: 86-571-87039693
Ms.Sally
Tel: 86-15869146940
Ms.Jenna
Tel: 86-13588046690
Ms.Nikita
Tel: 86-13530914499
Ms.Lillian
Tel: 86-18958617060
Ms.Lisa
Tel: 18814867632
Ms.Vivian
Tel: 18852815239
  • Fax: 86-571-87035681
  • URL: http://www.sartort.com
  • Province/state: Zhejiang
  • City: Hangzhou
  • Street:No. 57, Tech Park Road, Hangzhou, Zhejiang, China
  • MaxCard:
Home > Products > 

fast delivery 1809249-37-3 Reliable quality

fast delivery 1809249-37-3 Reliable quality CAS NO.1809249-37-3

  • FOB Price: USD: 11,500.00-12,500.00 /Kilogram Get Latest Price
  • Min.Order: 1 Kilogram
  • Payment Terms: L/C,T/T,MoneyGram
  • Available Specifications:

    99%(1-25)Kilogram99%(26-100)Kilogram

  • Product Details

Keywords

  • fast delivery 1809249-37-3
  • Reliable quality Remdesivir
  • 1809249-37-3 Remdesivir

Quick Details

  • ProName: fast delivery 1809249-37-3 Reliable qu...
  • CasNo: 1809249-37-3
  • Molecular Formula: C27H35N6O8P
  • Appearance: White solid powder
  • Application: Coronavirus;Covid-19
  • DeliveryTime: 5-7days
  • PackAge: 25kg/drum
  • Port: Any port in China
  • ProductionCapacity: 1 Metric Ton/Month
  • Purity: 99%
  • Storage: Room temperature
  • Transportation: Express/Sea/Air
  • LimitNum: 1 Kilogram
  • Moisture Content: ≤0.5%

Superiority

fast delivery 1809249-37-3 Reliable quality 

      Process Capability :   Sartort Biopharma's chemists are skilled at performing complex, multi-step syntheses and producing and sell unique chemicals around the world. 1, we are able to concentracted size and low overheads, we are able to offer prompt quotations, very competitive prices, high quality products and fast delivery. 2, All chemicals are typically >97% , For building blocks, The structure and purity is confirmed by NMR and LC-MS. Intermediates and final products are analyzed by GC, HPLC, IR, NMR, MS, elemental analysis, atom-absorpting analysis and crystallographical methods.

     Sartort Biopharma is a leading company engaging in the production of Intermediates, fine chemicals, Ionic liquids and 3D printing materials. It has such controlled subsidiaries as Sartort Pharma and Sartort Advanced Material,analytical laboratories, and an 10,000 m2 facility housing our process R&D labs, kilo lab and pilot plant, we have the skills, knowledge and experience to meet your kilo/commercial scale manufacturing needs.We would appreciate the opportunity to work with your company by providing the best quality, service, and technical support with very competitive pricing.

    Sartort Biopharma has its own factory and is a large-scale chemical industry company integrating production and sales, and is the industry leader in China. We can achieve fast shipping and fast delivery. This is one of our strengths. At the same time, because we are direct sales from the factory, our price is the ex-factory price, which is much lower than the market price. This is our second advantage. In addition, our scientific research team strictly controls every link of production to ensure high-quality and reliable  quality. We also passed the CAS assessment, which is quite authoritative. Reliable quality is our third advantage.

     Looking forward to cooperating with you, please feel free to contact us.

     Contact US

Mr.Bob Yu
Tel: 86-571-28069376
Ms.Sally
Tel: 86-15869146940
Ms.Jenna
Tel: 86-13588046690
Ms.Nikita
Tel: 86-13530914499
  • Fax: 86-571-87035681
  • Province/state: Zhejiang
  • City: Hangzhou
  • Street:914-915, Bldg. 16, No. 57, Tech Park Road, Baiyang Street, Economic And Technological Development Zone

 

     

    

    

Details

fast delivery 1809249-37-3 Reliable quality 

     Remdesivir (Remdesivir) is a nucleoside analog and is an inhibitor of RNA-dependent RNA polymerase (RdRp), which can inhibit viral nucleic acid synthesis and anti-virus. The current clinical Chemicalbook bed study for Ebola virus infection is in phase II. MERS-infected mice performed much better after receiving this combination therapy, with reduced virus replication and improved lung function. Recent studies have shown that Remdesivir has a certain active effect on inhibiting the new coronavirus.

    Application status
 
    Remdesivir is a nucleotide analog prodrug. In vitro experiments and animal model data indicate that Redecive inhibits SARS (SARS coronavirus) and Middle East respiratory syndrome (MERS coronavirus) by inhibiting RNA-derived RNA polymerase (RdRp). , Chemicalbook Ebola coronavirus and many other coronaviruses. In vitro cell experiments show that the median effective concentration (IC50) of Radixivir against the new coronavirus is 0.77μmol·L-1. However, Remdesivir has not been approved for marketing in any country, and its effectiveness and safety have not been confirmed by phase III clinical trials, and only phase II clinical trials have been carried out for Ebola virus.
 
   Biological activity
    Remdesivir (GS-5734) is a nucleoside analog with antiviral activity. In HAE cells, the EC50 value of SARSChemicalbook-CoV and MERS-CoV is 74nM. In delayed brain tumor cells, it has antiviral activity. 
The EC50 value is 30 nM.
 
     Product advantage introduction:
     Remdesivir is a nucleoside analogue being researched by Gilead Sciences. On May 7, 2020, the Japanese government approved Gilead Sciences (GILD.US) drug Remdesivir for the treatment of new crowns Viral drugs have become the country's first officially approved drug for the treatment of new coronavirus-related diseases, and priority is given to severely ill patients. 
Remdesivir has not been licensed or approved in countries other than Japan. In May 2020, Remdesivir was authorized by the U.S. Food and Drug Administration (FDA) with an emergency use authorization (EUA). Although it has not been officially approved by the FDA, its Chemicalbook has a very broad market prospect and has certain strategic drug value. Remdesivir has broad-spectrum antiviral activity. It has shown its effect on a variety of emerging viral pathogens in in vitro and in vivo studies in animal models, including Ebola virus, Marburg virus, and Middle East respiratory syndrome (MERS 
) And atypical pneumonia (SARS) viruses, so remdesivir may play a therapeutic role in epidemics caused by similar viruses in the future. At present, Remdesivir has been approved for use in various forms in 41 countries and regions including the United States, Japan, the United Kingdom, the European Union, the United Arab Emirates, India and Canada.
Product advantage introduction:
     Remdesivir is a nucleoside analogue being researched by Gilead Sciences. On May 7, 2020, the Japanese government approved Gilead Sciences (GILD.US) drug Remdesivir for the treatment of new crowns Viral drugs have become the country's first officially approved drug for the treatment of new coronavirus-related diseases, and priority is given to severely ill patients. 
Remdesivir has not been licensed or approved in countries other than Japan. In May 2020, Remdesivir was authorized by the U.S. Food and Drug Administration (FDA) with an emergency use authorization (EUA). Although it has not been officially approved by the FDA, its Chemicalbook has a very broad market prospect and has certain strategic drug value. Remdesivir has broad-spectrum antiviral activity. It has shown its effect on a variety of emerging viral pathogens in in vitro and in vivo studies in animal models, including Ebola virus, Marburg virus, and Middle East respiratory syndrome (MERS 
) And atypical pneumonia (SARS) viruses, so remdesivir may play a therapeutic role in epidemics caused by similar viruses in the future. At present, Remdesivir has been approved for use in various forms in 41 countries and regions including the United States, Japan, the United Kingdom, the European Union, the United Arab Emirates, India and Canada.
 
Density 1.47±0.1 g/cm3(Predicted)
 
Acidity coefficient (pKa) 12.00±0.70 (Predicted)
 
   
Product name  Remdesivir
Cas number  1809249-37-3
Molecular formula C27H35N6O8P
Molecular weight 602.58
Appearance White solid powder
Loss on drying 0.5%
Residue in ignition ≤0.1%
Individuel impurity 0.1%
Total impurities 1.0%
Specific Rotation -19°~ -22°
Assay 98.0%~101.0%
 
our client.jpg
     

Other products of this supplier